Sarepta Therapeutics Q4 Loss More Than Triples on a Doubling in Expenses

Sarepta Therapeutics loss widens as its expenses soar, but the company is nearing clarity on its phase 3 trial design for lead drug eteplirsen.

Feb 27, 2014 at 12:12PM

Clinical-stage RNA-based therapeutics developer Sarepta Therapeutics (NASDAQ:SRPT) reported its fourth-quarter earnings results before the opening bell this morning, highlighting significantly higher expenses and a widened quarterly loss.

For the quarter, revenue fell 64% to $2.63 million due to the discontinuation of the Ebola portion of its Ebola-Marburg U.S. government contract. Sarepta also notes that while the Marburg portion was unaffected by this termination, revenue from this portion decreased during the quarter due to the timing of certain activities throughout the life of the contract. Declines from this contract were slightly offset by revenue obtained in the EU from its SKIP-NMD agreement, which is researching an exon 53 skipping therapeutic.

Adjusted net loss for the quarter more than tripled to $29.1 million, or $0.77 per share, from $8.9 million, or $0.34 per share, in the year-ago quarter. Sarepta notes that the combination of lower revenue and significantly higher expenses due to corporate growth widened its loss. Specifically, research and development expenses jumped 95% to $25.1 million while general and administrative costs soared 114% to $10.4 million.

With much of the company's valuation tied to eteplirsen, its Duchenne muscular dystrophy drug hopeful, investors will also want to note that CEO Chris Garabedian anticipates, "continued discussions with the FDA to gain clarity in the coming weeks on the clinical path forward for eteplirsen."

As with all clinical-stage biopharmaceutical companies, cash and cash burn are important. Sarepta ended the fiscal year with $264.9 million in cash, cash equivalents, and restricted investments. This compares favorably with the $187.7 million it ended fiscal 2012 with, and was bumped higher primarily by the $125 million it raised in an at-the-market share offering of 3.4 million shares in July.

Looking ahead toward fiscal 2014, Sarepta is forecasting a loss from operations of $110 million-$120 million, which is fairly consistent with the $112 million loss reported for fiscal 2013 this morning.


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information